BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 31781855)

  • 1. Identification of candidate genes and miRNAs for sensitizing resistant colorectal cancer cells to oxaliplatin and irinotecan.
    Poorebrahim M; Sadeghi S; Ghanbarian M; Kalhor H; Mehrtash A; Teimoori-Toolabi L
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):153-171. PubMed ID: 31781855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Plasma microRNA miR-1914* and -1915 Suppresses Chemoresistant in Colorectal Cancer Patients by Down-regulating NFIX.
    Hu J; Cai G; Xu Y; Cai S
    Curr Mol Med; 2016; 16(1):70-82. PubMed ID: 26695693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Through oxaliplatin resistance induction in colorectal cancer cells, increasing ABCB1 level accompanies decreasing level of miR-302c-5p, miR-3664-5p and miR-129-5p.
    Ghanbarian M; Afgar A; Yadegarazari R; Najafi R; Teimoori-Toolabi L
    Biomed Pharmacother; 2018 Dec; 108():1070-1080. PubMed ID: 30372807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-193a-5p as a promising therapeutic candidate in colorectal cancer by reducing 5-FU and Oxaliplatin chemoresistance by targeting CXCR4.
    Azar MRMH; Aghazadeh H; Mohammed HN; Sara MRS; Hosseini A; Shomali N; Tamjidifar R; Tarzi S; Mansouri M; Sarand SP; Marofi F; Akbari M; Xu H; Shotorbani SS
    Int Immunopharmacol; 2021 Mar; 92():107355. PubMed ID: 33429333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The c-Myc/miR-27b-3p/ATG10 regulatory axis regulates chemoresistance in colorectal cancer.
    Sun W; Li J; Zhou L; Han J; Liu R; Zhang H; Ning T; Gao Z; Liu B; Chen X; Ba Y
    Theranostics; 2020; 10(5):1981-1996. PubMed ID: 32104496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-122 Targets X-Linked Inhibitor of Apoptosis Protein to Sensitize Oxaliplatin-Resistant Colorectal Cancer Cells to Oxaliplatin-Mediated Cytotoxicity.
    Hua Y; Zhu Y; Zhang J; Zhu Z; Ning Z; Chen H; Liu L; Chen Z; Meng Z
    Cell Physiol Biochem; 2018; 51(5):2148-2159. PubMed ID: 30522111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypermethylated and downregulated MEIS2 are involved in stemness properties and oxaliplatin-based chemotherapy resistance of colorectal cancer.
    Wang X; Ghareeb WM; Zhang Y; Yu Q; Lu X; Huang Y; Huang S; Sun Y; Chi P
    J Cell Physiol; 2019 Aug; 234(10):18180-18191. PubMed ID: 30859572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis.
    Hsu HH; Chen MC; Baskaran R; Lin YM; Day CH; Lin YJ; Tu CC; Vijaya Padma V; Kuo WW; Huang CY
    J Cell Physiol; 2018 Jul; 233(7):5458-5467. PubMed ID: 29247488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNAs as potential therapeutic targets to predict responses to oxaliplatin in colorectal cancer: From basic evidence to therapeutic implication.
    Moradi Marjaneh R; Khazaei M; Ferns GA; Avan A; Aghaee-Bakhtiari SH
    IUBMB Life; 2019 Oct; 71(10):1428-1441. PubMed ID: 31322820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNAs predict and modulate responses to chemotherapy in colorectal cancer.
    Yu X; Li Z; Yu J; Chan MT; Wu WK
    Cell Prolif; 2015 Oct; 48(5):503-10. PubMed ID: 26202377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell Lines.
    Ginés A; Bystrup S; Ruiz de Porras V; Guardia C; Musulén E; Martínez-Cardús A; Manzano JL; Layos L; Abad A; Martínez-Balibrea E
    PLoS One; 2015; 10(5):e0123830. PubMed ID: 25955657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Differentially Expressed MicroRNAs involved in the Pathogenesis of Colorectal Cancer.
    Feng H; Xu M; Zhang Y; Han B; Wang J; Sun P
    Clin Lab; 2018 May; 64(5):797-804. PubMed ID: 29739047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LEF1 silencing sensitizes colorectal cancer cells to oxaliplatin, 5-FU, and irinotecan.
    Fakhr E; Zare F; Azadmanesh K; Teimoori-Toolabi L
    Biomed Pharmacother; 2021 Nov; 143():112091. PubMed ID: 34474344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TGM2, HMGA2, FXYD3, and LGALS4 genes as biomarkers in acquired oxaliplatin resistance of human colorectal cancer: A systems biology approach.
    Cheraghi-Shavi T; Jalal R; Minuchehr Z
    PLoS One; 2023; 18(8):e0289535. PubMed ID: 37535601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpressed CES2 has prognostic value in CRC and knockdown CES2 reverses L-OHP-resistance in CRC cells by inhibition of the PI3K signaling pathway.
    Zhang Y; Sun L; Sun Y; Chen Y; Wang X; Xu M; Chi P; Xu Z; Lu X
    Exp Cell Res; 2020 Apr; 389(1):111856. PubMed ID: 31981591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-Drug Interactions of Irinotecan, 5-Fluorouracil, Folinic Acid and Oxaliplatin and Its Activity in Colorectal Carcinoma Treatment.
    Zoetemelk M; Ramzy GM; Rausch M; Nowak-Sliwinska P
    Molecules; 2020 Jun; 25(11):. PubMed ID: 32512790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Translationally controlled tumour protein TCTP is induced early in human colorectal tumours and contributes to the resistance of HCT116 colon cancer cells to 5-FU and oxaliplatin.
    Bommer UA; Vine KL; Puri P; Engel M; Belfiore L; Fildes K; Batterham M; Lochhead A; Aghmesheh M
    Cell Commun Signal; 2017 Feb; 15(1):9. PubMed ID: 28143584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-483-3p regulates oxaliplatin resistance by targeting FAM171B in human colorectal cancer cells.
    Liang H; Xu Y; Zhang Q; Yang Y; Mou Y; Gao Y; Chen R; Chen C; Dai P
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):725-736. PubMed ID: 30861353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular implications of MUC5AC-CD44 axis in colorectal cancer progression and chemoresistance.
    Pothuraju R; Rachagani S; Krishn SR; Chaudhary S; Nimmakayala RK; Siddiqui JA; Ganguly K; Lakshmanan I; Cox JL; Mallya K; Kaur S; Batra SK
    Mol Cancer; 2020 Feb; 19(1):37. PubMed ID: 32098629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan.
    Boyer J; McLean EG; Aroori S; Wilson P; McCulla A; Carey PD; Longley DB; Johnston PG
    Clin Cancer Res; 2004 Mar; 10(6):2158-67. PubMed ID: 15041737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.